Dr. Neil Hayward, co-founder, President, and CEO at eXIthera Pharmaceuticals, Inc., discusses the need for a new anti-thrombotic drug and how eXIthera is addressing that need with their lead product candidate EP-7041. The next step for EP-7041 is Phase 2 clinical trials on cardiac surgery patients.
Dr. Neil J. Hayward, Ph.D. is the co-founder, President, and Chief Executive Officer at eXIthera Pharmaceuticals, Inc. He has over 30 years of experience in discovery and preclinical research and development. Dr. Hayward holds his B.Sc. from the University of London and his M.Phil. and Ph.D. in Pharmacology from the University of Cambridge, UK.